Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian O Rodriguez

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Dermatology and Therapy|June 3, 2025
Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective StudyAdrian O Rodriguez, Caid Sterling Smith
Skinmed|December 9, 2010
Segmental cutaneous piloleiomyomataRobert H Cook-Norris, Adrian O Rodriguez, Bradley T Kovach, et al.
Dermatology and Therapy|March 2, 2026
The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE StudyAndrew Alexis, Amy McMichael, Neelam Vashi, et al.
JAMA Dermatology|December 11, 2024
Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality ImprovementAndrew Alexis, Amy McMichael, Neelam Vashi, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical TrialAmy McMichael, Mona Shahriari, Linda Stein Gold, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Dermatology and Therapy|June 3, 2025
Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective StudyAdrian O Rodriguez, Caid Sterling Smith
Skinmed|December 9, 2010
Segmental cutaneous piloleiomyomataRobert H Cook-Norris, Adrian O Rodriguez, Bradley T Kovach, et al.
Dermatology and Therapy|March 2, 2026
The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE StudyAndrew Alexis, Amy McMichael, Neelam Vashi, et al.
JAMA Dermatology|December 11, 2024
Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality ImprovementAndrew Alexis, Amy McMichael, Neelam Vashi, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical TrialAmy McMichael, Mona Shahriari, Linda Stein Gold, et al.
Pageof 1